Differential expression and functional analysis of circular RNAs and m6A modifications in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
Abstract Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) in childhood is associated with dismal outcomes, in large part due to challenges in diagnosis and monitoring therapeutic efficacy. Recent studies suggest that circular RNAs (circRNAs) are potential diagnostic and pro...
Saved in:
| Main Authors: | Lichun Xie, Ye Xu, Chuiqin Fan, Maochuan Liao, Guichi Zhou, Chen Fen, Lian Ma, Fei-Qiu Wen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-97345-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
B-Lymphoblastic Leukemia Presenting with an Isoderivative Philadelphia Chromosome—A Rare Case Report and Review of Literature
by: Neelum Mansoor, et al.
Published: (2025-02-01) -
Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Jung Min Lee, et al.
Published: (2025-01-01) -
Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD
by: Jing Lu, et al.
Published: (2025-02-01) -
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry
by: Timothy Devos, et al.
Published: (2025-12-01) -
Quality‐Adjusted Time Without Symptoms of Disease or Toxicity (Q‐TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
by: Ajibade Ashaye, et al.
Published: (2025-04-01)